|
Clinically integrated
|
|
|
| PD-L1 expression by IHC |
Pan-cancer, NSCLC, urothelial carcinoma, triple-negative breast cancer |
(18, 21-23) |
| MSI |
Pan-cancer, colorectal cancer |
(39, 42, 43) |
| TMB |
Pan-cancer, melanoma, NSCLC |
(14, 26-30) |
|
Emerging and context-specific
|
|
|
| Clonal TMB |
Pan-cancer |
(36, 44, 45) |
| MANA quality |
Pan-cancer |
(53, 54, 59, 61, 62) |
| HLA diversity |
Pan-cancer |
(37, 64, 65) |
| Oncogenic drivers of immune suppression (PTEN, Wnt, JAK1/2, STK11, MYC, and EGFR) |
Pan-cancer |
(37, 73-76) |
| Neoantigen loss |
NSCLC |
(85) |
| Gene expression profiles |
Pan-cancer |
(87) |
| Tertiary lymphoid structures |
Melanoma, renal cell carcinoma, sarcoma |
(88-90) |
| T cell repertoire |
Pan-cancer |
(96, 97) |
| ctDNA |
Pan-cancer |
(99, 102-104, 108, 109, 113, 114) |
